GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » EBITDA per Share

AVANIR Pharmaceuticals (FRA:AV2B) EBITDA per Share : €-0.21 (TTM As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals EBITDA per Share?

AVANIR Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2014 was €-0.06. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €-0.21.

During the past 3 years, the average EBITDA per Share Growth Rate was -17.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -1.40% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for AVANIR Pharmaceuticals's EBITDA per Share or its related term are showing as below:

FRA:AV2B' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0   Med: -16.6   Max: 223.2
Current: -17.6

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of AVANIR Pharmaceuticals was 223.20% per year. The lowest was 0.00% per year. And the median was -16.60% per year.

FRA:AV2B's 3-Year EBITDA Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.75 vs FRA:AV2B: -17.60

AVANIR Pharmaceuticals's EBITDA for the three months ended in Sep. 2014 was €-9.98 Mil.

During the past 3 years, the average EBITDA Growth Rate was -8.80% per year. During the past 5 years, the average EBITDA Growth Rate was 13.30% per year. During the past 10 years, the average EBITDA Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of AVANIR Pharmaceuticals was 265.80% per year. The lowest was 0.00% per year. And the median was 3.50% per year.


AVANIR Pharmaceuticals EBITDA per Share Historical Data

The historical data trend for AVANIR Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals EBITDA per Share Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.37 -0.34 -0.37 -0.22

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.05 -0.05 -0.05 -0.06

AVANIR Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

AVANIR Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Sep. 2014 is calculated as

EBITDA per Share(A: Sep. 2014 )
=EBITDA/Shares Outstanding (Diluted Average)
=-35.478/161.269
=-0.22

AVANIR Pharmaceuticals's EBITDA per Share for the quarter that ended in Sep. 2014 is calculated as

EBITDA per Share(Q: Sep. 2014 )
=EBITDA/Shares Outstanding (Diluted Average)
=-9.983/172.353
=-0.06

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals  (FRA:AV2B) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


AVANIR Pharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines